Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Intermolecular complementation achieves high-specificity tumor targeting by anthrax toxin.

Shihui Liu1, Vivien Redeye, Jeffrey G Kuremsky

  • 1Microbial Pathogenesis Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892.

Nature Biotechnology
|May 17, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patient-derived organoids reveal ductal dysfunction and CFTR-modulator responses in chronic pancreatitis.

Cell stem cell·2026
Same author

Highly cited original research in microneedle science from 2015 to 2025 a bibliometric and altmetric analysis.

Discover nano·2026
Same author

SO<sub>2</sub>-Mediated Decarboxylative C(sp<sup>3</sup>)-C(sp<sup>3</sup>) Coupling of Carboxylic Acids Enabled by Photoredox Catalysis.

Chemistry, an Asian journal·2026
Same author

Correction: The effectiveness of nano chemotherapeutic particles combined with mifepristone depends on the PR isoform ratio in preclinical models of breast cancer.

Oncotarget·2026
Same author

Genome sequence of protease-free <i>Bacillus</i> subtilis KO7-S strain created for protein production.

Microbiology resource announcements·2026
Same author

Genome sequence of protease-free <i>Bacillus anthracis</i> BH500 strain created for protein production.

Microbiology resource announcements·2026

Engineered anthrax toxin components (PrAg) can be designed to selectively target tumors. When combined, these components form functional toxin-binding sites only within tumor cells, reducing toxicity and enhancing therapeutic effectiveness.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Anthrax toxin protective antigen (PrAg) forms a heptamer, with the lethal factor (LF) binding site spanning two adjacent monomers.
  • This structure suggests potential for targeted drug delivery by engineering PrAg monomers that only form functional LF-binding sites through intermolecular complementation.

Purpose of the Study:

  • To develop a tumor-targeting system using engineered anthrax toxin components with enhanced cell-type specificity.
  • To investigate the therapeutic potential of specifically complemented PrAg variants against aggressive transplanted tumors.

Main Methods:

  • Created PrAg mutants with altered LF-binding subsites and incorporated urokinase plasminogen activator (uPA) or matrix metalloproteinase (MMP) cleavage sites.
  • Administered mixtures of complementing PrAg variants to tumor cells expressing uPA and MMP.

Related Experiment Videos

  • Assessed toxicity in mice and therapeutic efficacy against transplanted tumors.

    • Main Results:

    • Individual PrAg mutants exhibited low toxicity due to impaired LF binding.
    • Co-administration of complementing PrAg variants led to the assembly of functional LF-binding heteroheptamers specifically in uPA- and MMP-expressing tumor cells.
    • The combined PrAg variants demonstrated significantly reduced toxicity in mice and high efficacy in treating aggressive transplanted tumors.

    Conclusions:

    • Engineered anthrax toxin components can achieve high cell-type specificity for tumor targeting through intermolecular complementation.
    • This approach offers a strategy for developing potent and selective cancer therapeutics with improved therapeutic indices.
    • Multimeric toxins provide a versatile platform for introducing multiple specificity determinants for targeted therapies.